Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Midi Health vs Vea Health

Midi Health
Graded #413

Higher grade

vs+1.3999999999999986
Vea Health
Graded #450

Lower grade

The verdict

Midi Health takes it — 56.4/100 to 55/100, but only just.

Midi Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Midi Health is a nationwide 50-state menopause and perimenopause telehealth platform. Vea Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationVea Health +11
40
51
Clinical oversightMidi Health +12
78
66
Labs & monitoringEven
52
52
FulfillmentMidi Health +10
78
68
Contract termsEven
55
55
Midi Health · left barVea Health · right bar

The numbers

MetricMidi HealthVea Health
WeighScore56.4/10055/100
GradeCC
Scorecard rank#413#450
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Midi Health

Graded #413 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss
Vea Health

Graded #450 · C

Strengths

  • Publishes the FDA compounded-medication disclaimer
  • Oral and injection protocols for both semaglutide and tirzepatide
  • Claims 50-state coverage via a clinician network
  • Clearly differentiated positioning (longevity, men's health, performance)

Where it loses points

  • Pricing not shown until after sign-up
  • Pharmacy partner not named (only 'U.S.-based pharmacy')
  • LegitScript certification status not visible
  • No named medical director
  • 503A vs 503B designation not specified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard